According to a 2006 estimate, 18% of the global cancer burden is attributable to infectious agents, but almost every indication is that this figure is far too conservative.1) Researchers confined by the logic of Koch's postulatesCentury-old criteria designed to establish a causal relationship between a causative microbe and a disease. Koch's belief that only one pathogen causes one disease has now been called into question as multiple postulates are increasingly considered out of date. have looked for a single microbe causing a single disease. Evidence suggests, however, that it is communities of microbes that are responsible for cancer. According to the Marshall PathogenesisA description for how chronic inflammatory diseases originate and develop., chronic microbes persist, in large part, by dysregulating the Vitamin D ReceptorA nuclear receptor located throughout the body that plays a key role in the innate immune response. (VDRThe Vitamin D Receptor. A nuclear receptor located throughout the body that plays a key role in the innate immune response.), a key nuclear receptorIntracellular receptor proteins that bind to hydrophobic signal molecules (such as steroid and thyroid hormones) or intracellular metabolites and are thus activated to bind to specific DNA sequences which affects transcription. with a well-characterized role in both the innate immune responseThe body's first line of defense against intracellular and other pathogens. According to the Marshall Pathogenesis the innate immune system becomes disabled as patients develop chronic disease. and metastasis suppression. Indeed one of the hallmarks of cancer is a disruption in the vitamin D endocrine system including high 1,25-DPrimary biologically active vitamin D hormone. Activates the vitamin D nuclear receptor. Produced by hydroxylation of 25-D. Also known as 1,25-dihydroxycholecalciferol, 1,25-hydroxyvitamin D and calcitirol. and slowed activity of the receptor. As they progressively multiply through a process known as successive infectionAn infectious cascade of pathogens in which initial infectious agents slow the immune response and make it easier for subsequent infections to proliferate., microbes elicit an inflammatory response, a response which has been shown to increase over time the risk of metastasis.

Several patients have worked with their doctors to treat their cancer with the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis.. However, the MP appears to be most effective as a preventative measure.

It may be particularly important for MP patients with cancer in the family to avoid caffeine as far as possible.

“It is difficult to assess the practical significance of phagocytic suppression, but our previous work (unpublished) has shown that cancer cells can suppress phagocytosis in a similar manner. If this is the case, caffeine may be aiding in the suppression of immune response in the tumor microenvironment.” 2)

Evidence of infectious cause

According to D.L. Mager, “An overwhelming body of evidence has determined that relationships among certain bacteria and cancers exist.”3)

Infections and cancer: the “fifty shades of immunity” hypothesis

The growing number of examples of microbes associated with cancers include:

  • breast cancer – Underscoring how cancer is a systemic disease, a 2006 study found that the gut bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice.4)
  • colon cancerStreptococcus bovis and E. coli
  • colorectal cancer – A 2011 study of the colon microbiotaThe bacterial community which causes chronic diseases - one which almost certainly includes multiple species and bacterial forms. in individuals with colon cancer versus those with a normal colonoscopy found a significant elevation of the Bacteroides/Prevotella population in cancer patients.5) Another study, this one performed in mice, showed that colitis (swelling of the large intestine) increases the risk of new colorectal tumors.6)
  • gastric cancer – Chronic H. pylori infection is the major risk factor for gastric cancer.7) 8)
  • liver cancer – It is “well established” that chronic infections with hepatitis B and C viruses (HBV, HCV) represent major risk factors for HCC.9)
  • lung cancer – According to a 2011 meta-analysis, patients exposed to C. pneumoniae infection had a 48% greater risk for lung cancer risk, relative to those not exposed.10)
  • prostate cancer – In a 2005 culture-based study, Cohen found that Propionibacterium acnes in 35% of prostate samples of 34 consecutive patients tested.11)
  • Table of cancers with associated agents. Infections and Cancer

With the recent advent of high throughput sequencing studies, we can expect additional insights into how diseases like cancer are associated with shifts in microbial communities. 12)

see also M P Study Site

Innate immunity

Macrophages are immune cells just like T and B cells, but differ in that they can eat cells that are not supposed to be in the body. In fact, they are the most prominent immune cell found in cancer, but unfortunately, most are often convinced to help cancer grow and spread. Cancer cells frequently stop macrophages from attacking them by expressing CD47, a “don't eat me” signal. Researchers now say that merely blocking inhibitory signals like CD47 is not always sufficient to convince macrophages to attack cancer. Instead, two signals are required. First, they need a signal to activate them—such as a toll-like receptor agonist. After that, a second signal—such as a CD47 inhibitor—can lower the threshold needed to wage battle on the cancer.

“It turns out macrophages need to be primed before they can go to work, which explains why solid tumors may resist treatment with CD47 inhibitors alone,” 13)

Increasing evidence supports the occurrence of an intriguing link between tumor onset and development with the microenvironment in which cancer cells are embedded. In this context, a critical role of CD73, in calibrating the duration, magnitude and composition of adenosine signaling in cancer development and progression, has been identified. 14)

The Vitamin D3Form of vitamin D made in the skin when exposed to light. Also available in fish and meat. This secosteroid is sometimes converted into 25-D. Also known as cholecalciferol and activated 7-dehydrocholesterol. analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells 15)

Vitamin D metabolism

We conclude that there is a deregulation of the Vitamin D signalling and metabolic pathways in breast cancer, favouring tumour progression. Thus, during mammary malignant transformation, tumour cells lose their ability to synthesize the active form of Vitamin D and respond to VDR-mediated Vitamin D effects, while increasing their ability to degrade this hormone.

N. Lopes, VDR Signalling Disrupted in Breast Cancer16)

According to the Marshall Pathogenesis, communities of microbes gain a survival advantage by reducing expression of the nuclear receptorsIntracellular receptor proteins that bind to hydrophobic signal molecules (such as steroid and thyroid hormones) or intracellular metabolites and are thus activated to bind to specific DNA sequences which affect transcription. that play important roles in the innate immune response, particularly the Vitamin D Receptor (VDR). Wang et al.'s analysis17) found that the VDR transcribes at least 913 genes including TLR2A receptor which is expressed on the surface of certain cells and recognizes native or foreign substances and passes on appropriate signals to the cell and/or the nervous system. and the antimicrobial peptidesBody’s naturally produced broad-spectrum antibacterials which target pathogens. cathelicidin Family of antimicrobial peptides found primarily in immune cells and transcribed by the Vitamin D Receptor. and the beta-defensins. When this metagenome reduces expression of the host VDR, in order to protect the microbiota against the endogenous antimicrobials, it also knocks out transcription of a key gene involved in cancer – MTSS1.

Wang's expression map found that the number one gene transcribed by an active VDR is CYP24A1 (also known as CYP24) and the number two is MTSS1, also known as tumor metastasis suppressor protein, which ends up as the “missing in metastasis” (MIM) protein. Several 2011 studies stated that the VDR acts to suppress tumors in skin.18) 19)

The slowed activity of the VDR in cancer patients has been widely noted. Several researchers have observed that the Vitamin D Receptor (VDR) becomes inactive in cancer patients at just the time when it should be most active.20)

  • Pospechova et al. found low expression and no transcriptional activity of VDR in used choriocarcinoma cell lines. “In conclusion, our results suggest an epigenetic repression of VDR gene expression and activity in choriocarcinoma cell lines, and a non-genomic effect of 1,25(OH)(2)D(3) in JEG-3 cells.”21)
  • Lopes measured expression of the VDR, CYP27B1 and CYP24A1 of breast cancer by immunohistochemistry, finding levels of VDR expression were diminished in invasive tumours (56.2%).22)
  • High VDR expression in prostate tumors is associated with a reduced risk of lethal cancer, suggesting an important role of the vitamin D pathway in prostate cancer progression.23)

25-hydroxyvitamin D

Lower than normal levels of 25-DThe vitamin D metabolite widely (and erroneously) considered best indicator of vitamin D "deficiency." Inactivates the Vitamin D Nuclear Receptor. Produced by hydroxylation of vitamin D3 in the liver. have been generally associated with chronic disease but the field of oncology offers a number of counterexamples:

  • risk of prostate cancer – In a 2008 nested case-control study appearing in Journal of the National Cancer Institute, Ahn et al. found that patients with the lowest levels of 25-D also had the lowest risk of prostate cancer.24)
  • risk of breast cancer – In a 2011 study of nurses who were predominantly premenopausal, circulating 25-D levels were not significantly associated with breast cancer risk.
  • risk of pancreatic cancer – Patients with the highest levels of 25-D were at greatest risk of pancreatic cancer.25)
  • some rarer cancers26) – non-Hodgkin lymphoma or cancers of the endometrium, esophagus, stomach, kidney, ovary and pancreas
  • cancer mortality – A 2010 longitudinal study found that both high and low concentrations of plasma 25(OH)D were associated with elevated risks of overall and cancer mortality, and low concentrations are associated with cardiovascular mortality.27)

Are There Concerns About V.D Supplement ?

There is a common misconception that vitamin D supplementation is safe at any reasonable level, or that if some is good, more may be better.

  • It is clear that vitamin D intakes and serum 25(OH)D must be very high—perhaps 200-400 ng/mL—to cause the classic toxicity of marked hypercalcemia and kidney and liver damage.
  • However, emerging observational data suggest that adverse outcomes may occur at much lower levels, such as in the 50-75 ng/mL range. These suspected adverse outcomes appear to include increases in all-cause mortality and increases in the rate of heart disease and some cancers.

The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells 28)

Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. 29)

2014 a Cochrane meta-analysis that included 18 randomized clinical trials comparing vitamin D administration versus no intervention in healthy population found no difference regarding cancer incidence. In randomised controlled trials, relative risks for all cause mortality were 0.89 (0.80 to 0.99) for vitamin D3 supplementation and 1.04 (0.97 to 1.11) for vitamin D2Form of vitamin D created by plants and fungi. When ingested the secosteroid is (sometimes) converted into 25-D. Also known as ergocholecalciferol. supplementation. The effects observed for vitamin D3 supplementation remained unchanged when grouped by various characteristics. However, for vitamin D2 supplementation, increased risks of mortality were observed in studies with lower intervention doses and shorter average intervention periods. 30)

1,25-dihydroxyvitamin D

Mawer et al. reported that 1,25-D is such a sensitive indicator of the immune response that it can even be used to determine prognosis in breast cancer with bone metastasis.31) As the level of 1,25-D falls, the level of the innate immune system's ability to mount an immune response also falls, and the prognosis becomes less favorable. This seems to indicate that it might be possible to use the level of 1,25-D as one means of suggesting whether or not breast cancer treatment is effective if doctors know how to interpet the results. But, one should note that the patients in the above study had bone metastasis.

Hormonal changes result from change in 1,25 dihydroxyvitamin-D

Other Immune Suppressants

Women with hereditary cancer predispositions should put their smartphones, tablets, and laptops into air-plane mode at all times when not in use. 32)

Glioblastomas and malignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26 per 100,000 population. These tumors are typically associated with a dismal prognosis and poor quality of life. Only radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma. 33)

This compound has antiproliferative and antimigratory effects in squamous cell carcinoma, glioblastoma, and breast cancer cell lines 34)

Several researchers have highlighted a possible link between glioma and human cytomegalovirus (HCMV). 35)

Cell tower removed after 4 students get cancers

Officials Attempt To Block 5G Network Installation Over Health Risks

Microbial involvement

Single species vs. communities of microbes

Alicia H. Chang and Julie Parsonnet of Stanford University writes that a transmissible cause of cancer was suspected as early as the 16th century. It was not until the late 20th century definitively identified a bacterial cause of at least some types of cancer to most researchers' satisfaction.36) Identifying the full range of microbes which cause cancer, however, has been more challenging. To date, there have been a handful of cases that fulfill Koch's postulates (e.g., H. pylori and gastric cancer) where a single microbe is known to cause a single type of cancer. Consistent with Koch, researchers have tended to work in this vein, for example, looking at the 500+ species that inhabit the colon in the hopes of pinpointing the one and only bacterial species responsible for colorectal cancer.37)

A number of types of chronic infection have been observed to be associated with cancers in some studies, but without an identified specific bacterial pathogen. Examples are chronic ulcers and osteomylitis, sinus tracts (squamous cell carcinoma), chronic urinary tract infections (UTIs) (bladder cancer), and chronic prostatitis (prostate cancer).38)

The Marshall Pathogenesis is at complete odds with Koch's postulates, suggesting that it is not one species but entire communities of microbes that are responsible for many cancers. The process by which a person accumulates microbes responsible for disease is known as “successive infection.” In successive infection, an infectious cascade of pathogens progressively slow the immune response and allow for subsequent infections to proliferate, resulting in dysbiosis (microbial imbalances). According to this model, a single microbe may not need to be present in all cases of disease in order to be implicated in it.

Slow-growing microbes elicit inflammation

In almost all examples of bacterial inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. and human cancer, the implicated bacteria reside in the host for many years and create an environment of persistent inflammation. Specific bacteria that have been shown to cause chronic inflammation and an increased risk of cancer include Helicobacter pylori (gastric adenocarcinoma) and Salmonella enterica serovar Typhimurium or Paratyphi (biliary cancer).

Alicia H. Chang 39)

Chang offers several examples of why chronic microbes are key to cancer:

  • Helicobacter pylori and gastric cancer – A meta-analysis of 12 nested case-control studies found that there was a two times greater risk of gastric cancer for patients who had H. pylori. When serology was tested at least a decade before diagnosis, when the stomach might have been less disrupted by the progression to cancer, the relative risk was even greater: 4.9 times.40) In a cohort study in Japan that evaluated both intestinal-type and diffuse-type cancers, only H. pylori-infected subjects developed stomach cancer, making the risk ratio infinite.41)
  • Chlamydia trachomatis and cervical cancerChlamydia trachomatis is an obligate, intracellular, Gram-negative bacterium that can be transmitted sexually. Similar to the H. pylori serology studies of gastric cancer, the risk of cervical cancer with C. trachomatis infection is greater with increasing time from serum sampling to cancer diagnosis.42)
  • Colonic microflora and colon cancer – The best evidence supporting the inflammation theory in colorectal cancer is seen in the augmented risk of patients with inflammatory bowel diseases, i.e., ulcerative colitis and Crohn's disease. The cumulative incidence of colon cancer in IBD is as high as 18% at 30 years postdiagnosis.43) Epidemiologic studies show that the severity and duration of inflammation in IBD dictate cancer risk.44)
  • Neisseria gonorrhoeae and bladder cancer – Two case-control studies reported increased associated risk of 110% and 140%.45) 46) For comparison, syphilis, which does not cause urethritis, was also examined in one of the studies, and no association was found
  • Nonspecific urinary tract infections – The irritation caused by chronic urinary tract infections and chronic indwelling catheters has been implicated in bladder cancer in spinal cord injury patients.47)
  • Borrelia burgdorferi and MALT lymphoma of the skin – Studies from Scotland and Italy have reported an association between B. burgdorferi and primary cutaneous B-cell lymphoma (PCBCL), a type of MALT lymphoma. However, studies in the United States, Asia, and parts of Europe have found little evidence of B. burgdorferi in PCBCL patients. As Chang suggests, perhaps the variable prevalence of infection in PCBCL is explained by the different prevalences of Borrelia strains across the world or by differences in techniques used for detection of infection.48)

Inflammation induces cancer

According to Chang,49) Virchow first described the irritation hypothesis of carcinogenesis in the 19th century concluding that chronic irritation stimulated the cancer cells to grow. The inflammatory process is characterized by damage caused by the host's immune response to the infection rather than by the infecting organism itself. Over 100 years since Virchow's discoveries, the “chronic irritation hypothesis” remains a widely supported mechanism for carcinogenesis by infectious agents. Today the relationship between inflammation, innate immunityThe body's first line of defense against intracellular and other pathogens. According to the Marshall Pathogenesis the innate immune system becomes disabled as patients develop chronic disease. and cancer is widely accepted.50)

During a normal response to infection, inflammation is created as a means for the host to combat invading pathogens. Inflammation is first initiated by the recruitment of phagocytes to the site of infection. The phagocytes recruited to the site of infection also secrete proinflammatory cytokinesAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system., such as tumor necrosis factor alpha (TNF-alphaA cytokine critical for effective immune surveillance and is required for proper proliferation and function of immune cells.), and chemokines that attract more phagocytes and other cells of the immune system to the site of infection to amplify the inflammatory response. These cells respond through physiological processes mediated by the cellular enzymes NADPH oxidase, superoxide dismutase (SOD), myeloperoxidase, and nitric oxide synthase (NOS).

The result is the release of reactive oxygen and nitrogen oxide species (ROS and RNOS) to kill potential pathogens. The free radicals and secondary products derived from them, such as secondary amines, HNO2, N2O3, and peroxynitrite, may damage DNA, proteins, and cell membranes and indirectly induce cell repair. Areas of tissue injury and inflammation trigger regenerative cell division from tissue and marrow-derived stem cells. Increased cell division may lead to point mutations, deletions, or translocations as damaged DNA escapes the repair system; the aberrant DNA is then propagated by subsequent cell division. This can result in disordered cell differentiation and, ultimately, oncogenesis. Hence, chronic inflammation, caused by microbes, instigates a cycle of cell damage, repair, and compensatory proliferation that promotes the development of cancer cells.

Advanced stage follicular lymphoma (FL) is incurable by conventional therapies…… until intranodal injections of low-dose rituximab (5 mg), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor at the same lymphoma node.51)

Microbial interaction and disease

According to some sporadic reports, cancer regresses following spontaneous bacterial infection.52) Competition between an ever-changing mix of microbes, and the variable attention the immune system pays to any one component of that mix, may explain the waxing and waning of different cancerous states.

Natural killer cells “are cytotoxic lymphocytes specialized in early defense against virus-infected and transformed cells.” 53) and “are able to recognize and trigger cell death in tumors by detecting receptor expression abnormalities in transformed cells”. 54)

For example, H. pylori can cause gastric cancer or MALT lymphoma in some individuals. In contrast, exposure to H. pylori appears to reduce the risk of esophageal cancer in others. Salmonella typhi infection has been associated with the development of gallbladder cancer; however S. typhi has been associated with positive outcomes for melanoma, colon and bladder cancers.55)

Further, the live bacterium, Bacillus Calmette-Guérin (BCG) (see below), touted by some as a cancer vaccine, may also “work” by changing the path of successive infection, thus leading to immune disease (and cancers). After such an insult, the immune system focuses on Mycobacterium bovis (main component of BCG) and away from the chronic pathogens fueling the inflammation or cancer.

A similar dynamic is clear when it comes to autoimmune disease: lupus has been shown to inhibit the development of malaria (Plasmodium falciparum).56)

Metastatic communities parallel biofilm

Some have suggested provocatively that communities of metastatic cancerous cells closely resemble communities of microbes known as biofilm A structured community of microorganisms encapsulated within a self-developed protective matrix and living together..

We suggest that the quorum-sensing-controlled bacterial biofilm formation process closely parallels the steps in metastatic colonization. Cells migrate toward/on target surfaces (organ-specific homing), show cell-cell and cell-matrix interactions (tumor cell-stromal cell crosstalk), remain subclinical until they can mount an effective attack (dormancy), form complex structures with channels for nutrient flow (vascularized lesions), and contain resistant cells which can cause disease recurrence (persistors). Using ovarian cancer as an example, we present data supporting the connection between metastatic colonization and quorum sensing and discuss the implications for understanding and controlling metastasis formation.

Jonathan Hickson et al. 57)

Alternate explanations

Genes and mutations

Even researchers studying a high-priority, frequently studied disease such as cancer have failed to produce a telltale genetic association.

Genetic mutations are rampant in cancerous tissue: compared to tissue from a healthy age-matched control, a lung cancer patient may have as many as 50,000 genetic mutations.58) However, among the inherited cancer syndromes with no readily discernible environmental influence, it is thought that only 1-2% are caused by high penetrance (high-risk) human genes.59)

When diseases are not inherited in Mendelian ratios - somewhere between 0.01% and 0.001% of live births suffer from Mendelian diseases - geneticists have argued that those diseases are driven by effects reflecting a complicated interplay of human genes. But if a disease is a “genetic disease,” it should show very distinct patterns among twins, especially monozygotic (identical) twins. Because monozygotic twins are virtually identical in genetic makeup, the monozygotic twin concordance for such genetic diseases should be virtually 100 percent. For most diseases, this is not the case.60)

Monozygotic twins share the same genotype because they are derived from the same zygote. However, monozygotic twin siblings frequently present many phenotypic differences, such as their susceptibility to disease [italics added] … Recent studies suggest that phenotypic discordance between monozygotic twins is at least to some extent due to epigenetic [changes in gene expression caused by mechanisms other than changes in the underlying DNA sequence] factors that change over the lifetime of a multicellular organism.

P. Poulsen, et al. 61)

One study found that genetic concordance rates for identical twin pairs by age 75 years were only 11% for colorectal cancer, 13% for breast cancer and 18% for prostate cancer, and these were lower in dizygotic twins (5%, 9% and 3%, respectively).62) These low concordance rates agree with other data on cancer incidence and provide little support for strong heritable effects in cancer.63)

Infection with a bacteria called Helicobacter pylori has been widely recognized as the cause of stomach ulcers, but it is now thought to also cause stomach cancer.64) It's worth noting that the causative role H. pylori in stomach ulcers was not identified even though researchers were able to cultivate this bacterium in the laboratory and to see it under the microscope in gastric biopsies.

Persistent human papillomavirus infections have been recognized as the major cause of cervical cancer and may play a role in some cancers of the anus, vulva, vagina, and penis.65) Evolutionary biologist Paul Ewald has argued that infectious causation has often been accepted belatedly throughout the history of medicine and, if decades long trends are anything to go by, mainstream medicine will ultimately agree that the majority of cancers are caused by pathogens:

Back in 1975, mainstream medicine agreed that about 0.1% of human cancer cases were caused by pathogens. When it came to the rest of cases, their view was that they were probably caused by a combination of inherited predispositions and mutagens. Then in 1985, the percentage of cancer cases they tied to pathogens was 3%, and they continued to make the same argument about the remaining cases. In 1995 the percent of pathogen-induced cancer cases was accepted to be around 10%. Now, we’re at 20%. Still, mainstream medicine contends that the other 80% of cases do not have an infectious cause, but the question is – do you believe them anymore? In this sense, the clarity of hindsight can help a lot. Between evolutionary instinct and plain common sense we can view the issues of pathogens and cancer much more effectively.

Paul Ewald, PhD, Bacteriality.com

In a 2000 paper co-written with Ewald, Cochran and Cochran trace the long and seemingly inevitable acceptance of chronic diseases as being caused by infectious agents rather than genetic predisposition.66)

These findings suggest that pro-tumorigenic entotic engulfment activity is associated with mutant p53 expression, and the two combined are a key factor in genomic instability 67)


Smoking has been called “the single most preventable risk of disease” but the underlying disease process by which smoking is said to cause death and disease is not well-defined. However, there are several areas of study which point to the role of pathogens and modulation of the immune response in the diseases caused by smoking:

  • Pathogens have been detected in cigarettes.68)
  • Smoking has been shown to contribute to delayed apoptosis of immune cells as well as decrease production of antimicrobial peptides. Some evidence has emerged that smoking offers sick people symptomatic relief – through immunosuppression,69) an anti-inflammatory effect,70) or any number of other possible mechanisms.
  • Sick people are less likely to quit smoking, which may artificially inflate estimate of the harmful effect of tobacco. For example, schizophrenic patients, have reported that they smoked “primarily for sedative effects and control of negative symptoms of schizophrenia.”71) Symptomatic relief may also explain why people with mental illness are twice as likely to smoke than people without a mental illness.72)

→

Stress derived from interaction of particular personalities

in particular the empathic personality and the 'energy vampire'

from https://mpkb.org/home/social/talking#dealing_with_antagonism

Sadly, some people in your life may not want you to get well. For example, sometimes a partner or close friend can not tolerate change. Consciously or unconsciously they may undermine your efforts. It will be up to you to quietly persist, knowing that your recovery can only lead to a better outcome for both of you.

In an extreme case, there may be someone who is literally toxic, even socio-pathic. “Learn to value yourself, Learn to say No!” and if necessary, Remove yourself from the influence of any such person.

Marshall Protocol as a treatment for cancer?

The MP uses olmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. to activate the VDR, a nuclear receptor which is downregulated in cancer. While the MP appears to be a sensible preventive, it is not suitable for treating active metastasis.

While it is pretty certain that olmesartan reactivation of the VDR (and MTSS1) will likely reduce metastasis, that has little application once the cancerous cells have already started to spread. While the MP can probably stop metastasis from developing, once a tumor is in place, and growing, it is almost certainly too late to contemplate non-invasive therapies like the MP.

Trevor Marshall, PhD


This result provides a new idea on the anti-tumor mechanism of olmesartan, which may be used as a novel therapeutic target of cervical cancer. 73)

Research has shown that the renin-angiotensin system is implicated in a wide range of biological processes and diseases. Renin-angiotensin system and cancer

Safety of olmesartan

A 2010 meta-analysis of randomized controlled trials administering ARBs, the class of drugs (which olmesartan belongs to), concluded the the drugs were associated with a small increase in the incidence of cancer.74) This publication was widely rebuked, as one can see from the number of comments in PubMed referring to this article.

In the wake of the study, physicians contended that it is extremely unlikely that ARBs are associated with an increased risk of cancer, with one physician saying he has data that, if added to the analysis, would wipe out any cancer signal. (See also statement by Dr. Henry Black attesting to the safety of Benicar. Registration required.) Overall, they say, the media splash this paper has made could cause irreparable damage to the reputation of ARBs, which they consider vital tools in their armamentarium, and may unfortunately prompt many patients to stop taking the medicines, putting themselves at increased risk of cardiovascular and renal events.

Note also that the primary ARBs being evaluated, candesartan and telmisartan, have significantly different actions than olmesartan. According to the in silicoExperiment technique performed on computer or via computer emulation. emulations of Dr. Marshall, they are VDR antagonists.


analyses found no evidence that cancer risk increased with increasing duration of ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor. exposure (RR increase per year=0.99)

CONCLUSION: In this large nationwide cohort, use of ARBs was not significantly associated with increased risk of incident cancer overall or of lung cancer. 75)

Other treatments

Chemotherapy and radiation

Chemotherapy is aggressively immunosuppressive, and will allow a patient's bacterial load to return, by shutting down your immune system. For example, hepatitis infections76); also pneumocystis pneumonia have been known to become reactivated during chemotherapy.77)

Treatment for acute active Cancers

Toll-like receptor 9 (TLR9) agonists

The activity and safety of these novel anticancer agents are being explored in a wide range of tumor types as part of a variety of therapeutic strategies with the goal of harnessing the immune response to fight cancer. 78)

Activation of Toll-Like Receptor 9 by DNA from Different Bacterial Species 79)


Some physicians have recommended the Bacillus Calmette-Guérin (BCG) vaccine as a treatment for cancer. There is no evidence to support such an intervention. BCG is live bacterium, Mycobacterium bovis, and has been fingered as having directly caused sarcoidosis, for example.80) 81)

I understand your emotions regarding bladder cancer. I went through it but can now say I am convinced the MP has strengthened my immune system to prevent it again. My last two bladder scopes after surgery to remove tumors were negative (for the past year) and the FISH chromosomal test of the bladder wash was also negative for cancer. Take a look at my MP thread. I just posted an update earlier today. My doctor called Dr. Marshall and he explained to doc why BCG was not an option. I also declined chemo due to the disruption to the immune system. As Dr. Marshall said in a post the VDR transcribes an anti-metastasizing gene along with others to control/prevent cancer.

Gene, MarshallProtocol.com


Vitamin D

Main article: Vitamin D and cancer

A variety of studies have suggested that vitamin D protects against cancer. This seemingly intuitive proposition is supported by neither epidemiological nor molecular evidence. In fact, the very opposite is true. This article reviews why this body of research is most likely incorrect – or at the very least, much more complicated than articles in the popular media would have a person believe.

  • Latitude studies - The “latitude studies” are observational, as opposed to interventional, studies, which use ambient solar UV radiation as a proxy for latitude and vitamin D status. For these studies, researchers compare rates of certain major cancers - most notably breast, colorectal and prostate cancer - to rates of sunlight exposure. This group of research has the liability of being wildly inconsistent. The choice to publish research on a specific latitude gradient may be a better proxy for a researcher's bias.
  • Interventional studies - While some randomized controlled trials have suggested that consuming vitamin D reduces rates of cancer, larger and more carefully controlled studies show no such effect.
  • Studies of vitamin D status - Many of the studies examining the relationship between vitamin D status and incidence of cancer argue that low levels of 25-D contribute to cancer. This conclusion has been invalidated by larger well-controlled studies. Although the immune system works to downregulate 25-D (25-hydroxyvitamin D) in inflammatory diseases such as cancer, very high levels of 25-D are a clear indication of regular supplementation. Studies suggest that consuming large amounts of vitamin D predispose a person to increased incidence of cancer.
  • Observational studies – Some case control studies have found that vitamin D intake seems to increase incidence of certain types of cancer.

According to the Marshall Pathogenesis, alteration of vitamin D metabolism by a pathogenic microbiota prevents any benefit from vitamin D supplementation.

→

Vitamin E

Vitamin E supplementation and the risk of heart failure in women. 82)

Supplementation with vitamin E did not result in any significant improvements in prognostic or functional indexes of heart failure or in the quality of life of patients with advanced heart failure.83)

Canolol was found to counteract the fibrotic effects of vitamin E + CoQ10 on cardiac fibrosis in the context of a high-fat diet enriched with RSO. This effect occurred through a restoration of cardiac Ag2R-1b mRNA expression and decreased ischemia.84)


2018 Pawpaw contains acetogenins that can inhibit the growth of cancer cells. 85)

The 95% ethanol extract of the ripe fruit showed strong high inhibitory effect against various microorganisms. 86)

Gene therapy

Researchers trialling gene therapies against cancer have been unsuccessful to date. Such initiatives have yet to take into account the types of intracellular microbes implicated by the Marshall Pathogenesis. One, a Duke University program, to tailor cancer treatments to certain cancers has ended in disaster and lawsuits.

Screening and diagnosis

Cancer kills when it is “invasive,” spreading from primary sites to other sites and proliferating there. The only sure way to know the disease is cancer is to allow it to progress to a point where there is no question one has a proliferative disease. Clearly, this is not a tenable option as at a certain point, it is impossible to intervene. However, the risk of a false positive is also great. Chemotherapy will destroy the immune system, allowing microbes to multiply and leading to greater chronic inflammation when chemotherapy is discontinued. These two considerations have to be balanced, and it is a matter of debate whether many oncologists fully appreciate this balance. It is worth noting that false positives increase the apparent “success rate” of oncology, and there is therefore limited incentive to minimize them.

Papillary carcinomas are a special histological type of breast cancer, and have a relatively good outcome. 87)

Screenings not as effective as touted

  • mammograms for breast cancer – According to a 2009 BMJ analysis, the best evidence suggests that for every 2,000 women who are screened over 10 years, only one stands to have her life saved by the mammogram program, whereas the risk of getting an unnecessary breast cancer diagnosis is 10 times that. Gøtzsche has written a number of papers about the mismatch between mammograms' reputation and their track record for saved lives. For more, read the Reuters article or the article in the L.A. Times.
  • prostate cancer – According to a recommendation by the United States Preventive Services Task Force, healthy men should no longer receive a P.S.A. blood test to screen for prostate cancer because the test does not save lives over all and often leads to more tests and treatments that needlessly cause pain, impotence and incontinence in many. It is interesting to note, however, that in some individuals, levels of prostate specific antigen (PSA) rise shortly after acquisition of gonorrhea, nongonococcal urethritis, chlamydial infection, and trichomoniasis, suggesting prostatic inflammation.88)

If the public realized how high the false detection rate was, they would be more cautious, and not be hurried into surgery.

Trevor Marshall, PhD


In part because a missed diagnosis is so problematic, pathologists tend to err on the side of the false positives rather than false negatives. For example, it is not uncommon to receive a report that granuloma, which are found in sarcoidosis or Crohn's, are cancerous. Assuming that enlarged lymph nodes for illness (which naturally become enlarged during immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed.) are cancer is also frequent:


Colonoscopes are not contraindicated by the MP, and may be warranted for high risk patients. It is okay to continue MP medications but one may want to adjust them to reduce immunopathology.

Animal models

To date, animal models have had limited success to emulate cancers, particularly because the immune systems of even close relatives of humans are significantly different. For example, the infamous TeGenero study was initially trialled without a problem in apes. When it was introduced into the humans, it was a disaster.

Patient interviews

<html> <div class=“patientinterviews”>

<div class=“patientinterviewboxl”> <div class=“patientinterviewimage”></html><html></div> <div class=“patientinterviewtext”> <div class=“patientinterviewname”></html>Gene Johnson<html></div></html>

sarcoidosis, bladder cancer

Read the interview


<br clear=“left” />

</div> </html>

Interviews of patients with other diseases are also available.

Patients experiences

I was first diagnosed with Sarcoid in 1977, and like most of you have years of in and out of what seems like remission. To cut a long story short, I finally had a double mastectomy in 2006, and both my breasts came back from the lab, yes, with sarcoid throughout.

Debra, MarshallProtocol.com

My PSA was through the roof during the first 18 months on the MP (3 - 4 times the safe level). I had a biopsy and a colonoscopy, all were good. As the inflammation in my glands settled so did the PSA. It has fallen well within the safe zone and remained there for nearly 2 years. Hope this gives you some comfort, although my Dr was insistent that I get it checked to be sure.

Sydney Chris, MarshallProtocol.com

My prostate and urine flow issues started 20 years ago. I am pretty pleased with all my improvements on MP in that department. Although I never had an elevated PSA my gland was large enough that my urologist wanted to microwave it. Now it is normal size and typical upon rectal exam.

Polar Bear, MarshallProtocol.com

Proliferating breast cancer I found breast cancer in 1990, had a lumpectomy and follow up mastectomy with lymph node removal, as the cancer had begun to spread there. Similarly spreading, but in different organs, killed my mother at a slightly later stage of life. She had not sought treatment until too late. I have no doubt that prompt surgery and follow up radiotherapy and tamoxifen saved my life. At that period there were no alternatives or understanding of the microbiome.

Interestingly, I also developed a pre-cancerous site on my skin. This was removed in day surgery. Something appeared years later, about the size of a 5 cent piece close to the scar of the first. I was not alarmed, but watched it for any sign of change and reported to my doctor who was prescribing my Olmesartan according to the Marshall Protocol. She duly sent me to the skin specialist, who adopted a wait and see approach. (There would have been complications in skin surgery on that arm because of the lymphoedema developed due to air travel after the lymph node removal). After a couple of visits he took fine detail pictures of the changing blemish. One of these days I would like to go back and ask for these pictures, as a year later, the cancer had completely gone.

Pathology was unable to determine whether the diagnosis was Bowen's disease or Basal Cell Cancer. This did not surprise me as it seems common in MP patients for tests to behave differently to the general run of patients with similar conditions.

Sallie Q, MarshallProtocol.com

Recent research

Senescent cells contribute to both age-related degeneration and hyperplastic pathologies, including cancer. 89)

Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. 90)

Whey proteins and numerous growth factors that regulate insulin secretion, differentiation of intestine epithelium cells, and also tissue restoration, are priceless in stimulation the immune system.

Lactoferrin shows the most comprehensive pro-health properties: antioxidative, anticancer, immune stimulative and even chemopreventive. Also peptides and amino acids formed from casein and whey proteins possess immune stimulative activity. The most valuable proteins, i.e. lactoferrin, immune globulins, lactoperoxidase and lisozyme, together with bioactive peptides, are resistant to pepsin and trypsin activity. This is why they maintain their exceptional biological activity. 91)

Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. 92)

Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaBA protein that stimulates the release of inflammatory cytokines in response to infection pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future. 93)

In this large population-based gastro-oesophageal cancer cohort, we found moderately reduced cancer-specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required. 94)

miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. 95)

Therapeutic potentials of SCFA receptors [section 7 in 96) ] Recent progress in understanding the role of GPR41, GPR43 and GPR109A in health and disease demonstrate that these receptors do not just regulate inflammation and cancer in intestine, but also influence other gastrointestinal functions, allergies, adipogenesis, central nervous system and cardiovascular health.

review current evidence on the role of the human microbiotaThe bacterial community in the human body. Many species in the microbiota contribute to the development of chronic disease. in four cancer types (colorectal cancer, head and neck cancer, pancreatic cancer, and lung cancer) proposed as affected by both the oral and gut microbiota 97)

results suggest that the six lactic acid bacteria mixture from kefir has strong effects on natural immunity and tumor cell cytotoxicity98)

Using metabolomics, we investigated the metabolic influence that microbial biofilms A structured community of microorganisms encapsulated within a self-developed protective matrix and living together. have on colon tissues and the related occurrence of cancer.99)

Vitamin D and immune cells stimulate bone marrow disease 100)

a 10% increase in the proportion of ultra-processed foods in the diet was associated with a significant increase of greater than 10% in risks of overall and breast cancer. 101)

In this large prospective study, (101 257 participants aged 18 and over, mean age 42.2, SD 14.4; median follow-up time 5.1 years) the consumption of sugary drinks was positively associated with the risk of overall cancer and breast cancer. 100% fruit juices were also positively associated with the risk of overall cancer. These results need replication in other large scale prospective studies. They suggest that sugary drinks, which are widely consumed in Western countries, might represent a modifiable risk factor for cancer prevention. BMJ 2019;366:l2408

Read more

“The most serious health endpoints that have been reported to be associated with extremely low frequency (ELF) and/or radiofrequency radiation (RFR) include childhood and adult leukemia, childhood and adult brain tumors, and increased risk of the neurodegenerative diseases, Alzheimer’s and amyotrophic lateral sclerosis (ALS). In addition, there are reports of increased risk of breast cancer in both men and women, genotoxic effects (DNA damage, chromatin condensation, micronucleation, impaired repair of DNA damage in human stem cells), pathological leakage of the blood–brain barrier, altered immune function including increased allergic and inflammatory responses, miscarriage and some cardiovascular effects.”

Notes and comments


New Evidence Links Virus to Brain Cancer - https://www.med.wisc.edu/news-events/news/new-evidence-links-virus-to-brain-cancer/32922

Title:Microbiome and Malignancy

Authors: Plottel, CS; Blaser, MJ

Author Full Names: Plottel, Claudia S.; Blaser, Martin J.

Source: CELL HOST & MICROBE 10 (4): 324-335 OCT 20 2011

Language: English

Document Type: Review


Abstract: Current knowledge is insufficient to explain why only a proportion of individuals exposed to environmental carcinogens or carrying a genetic predisposition to cancer develop disease. Clearly, other factors must be important, and one such element that has recently received attention is the human microbiomeThe bacterial community in the human body. Many species in the microbiota contribute to the development of chronic disease., the residential microbes including Bacteria, Archaea, Eukaryotes, and viruses that colonize humans. Here, we review principles and paradigms of microbiome-related malignancy, as illustrated by three specific microbial-host interactions. We review the effects of the microbiota on local and adjacent neoplasia, present the estrobolome model of distant effects, and discuss the complex interactions with a latent virus leading to malignancy. These are separate facets of a complex biology interfacing all the microbial species we harbor from birth onward toward early reproductive success and eventual senescence.

well-established tumor-promoting function of chronic inflammation (Karin and Greten, 2005)103)

1000 types of cancer versus one

BRCA mutation genes

Question: I recently came across an article while doing a medline search entitled, “Association between low levels of 1,25 dihydroxyvitamin D and breast cancer risk.” The conclusions of the study were: “These data are consistent with a protective effect of 1,25-D for breast cancer in white women.” This concerns me because I carry the brca-1 mutation and so am already at a very high risk of getting breast cancer and according to the study lowering my 1,25-D will only further increase my risk.

The brca1 gene has only been shown to be a MARKER of breast cancer, not a cause. Second, Th1 inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. is almost certainly a necessary precursor to breast cancer (i.e. a cause) Mutations in brca1 and brca2 are associated with increased incidence of cancers, not necessarily causal.

I have just come from a “Diseases of (DNA) Transcription” conference at the Salk Institute where there was not one scientist who knew exactly how genes mutate, or why, or what it means.

Sure, there are statistics linking shifts in haplotypes with certain diseases, but they are just as likely due to the mix of persistent pathogens your family has been passing down, as they are due to any Mendelian variation of the gene pool.

A person has to assess the relative likelihood of dying from Th1 diseaseAny of the chronic inflammatory diseases caused by bacterial pathogens. and dying from cancer. 1,25-D is a measure of the Th1 reaction and is therefore intimately associated with breast cancer, in ways that this study investigators never dreamed of. If one doesn't understand the subtleties behind this kind of research, then one is going to have trouble assessing relative risks in medicine.

I have seen a number of Th1 patients erroneously diagnosed with cancer. The diagnosis of cancer is not precise. Flow cytometry senses the presence of both CD10 and bcl2, and these are elevated in Th1 disease. False positives are a fact of life, but patients rarely find out about them. False positives increase the apparent 'success rate' of oncology, and there is therefore little incentive to minimize them.

BRCA genes are turning out essentially useless to tell Breast Cancer predisposition, as now they are falling back on the old epidemiological factors before even screening :-(

The relationship between cancer and inflammation is controversial. (IMO) A good review of the issues is available from JOIMR

Additionally, two of the markers used in Flow Cytometry (used as the 'gold standard' for breast cancer) bcl2 and CD10, are both elevated in the inflammatory diseases, leading to misdiagnosis in a lot of cases, probably in a majority of cases. These misdiagnoses also bias the epidemiological studies.

The BRCA1 and BRCA2 genes are probably not good differential markers of cancer vs inflammation. The pathology report from MD Anderson again states there is no sign of proliferation of the cancer into the surrounding tissues, so the sentinel node biopsy is probably the best way to determine whether the lump is an old cancer or is still active.

Less than 10% of Breast cancers are due to BRCA1, most are due to Estrogen up-regulation. Since the Estrogen receptor transcribes the protein which folds to form the Vitamin D Receptor, excessive estrogen is probably associated with a disabled VDR, IMO.

~Trevor Marshall, PhD

BRCA1 and BRCA2 genes are no longer regarded as definitive

CHICAGO, Jan. 8,2008: BRCA genes get help in causing breast cancer-study

The risk of breast cancer among women carrying the well-known BRCA mutations is also affected by other genes, researchers said on Tuesday.

The study of close relatives of breast cancer patients who had one of the BRCA mutations showed the risk of the disease varied greatly between families, indicating that other genes must be involved.

So a woman who knows she has a BRCA1 or BRCA2 mutation still cannot know precisely what her risk of breast cancer is, the researchers reported in the Journal of the American Medical Association. “The implications of that are that there must be other genetic factors involved here,” Dr. Colin Begg of Memorial Sloan-Kettering Cancer Center in New York, who led the study, said in a telephone interview.

“Because if some carrier families have higher risks than other carrier families presumably there are other genes being passed through these families that elevate or lower the risks,” Begg said.

Begg's team studied 2,000 women diagnosed with breast cancer, and the families of the 181 patients who had BRCA mutations. They found that 5 percent of those with cancer in one breast had a BRCA1 or BRCA2 mutation and 15 percent of those with cancer in both breasts did.

All had been diagnosed early, before the age of 55. But only 25 percent of all the patients had a close relative with breast cancer. And 58 percent of those with BRCA1 or BRCA2 mutations had a mother, sister or other close relative with the disease, the researchers said.

They said this means a close relative of a BRCA carrier with breast cancer has a 40 percent risk of developing the disease herself by age 70. But this is an average risk and they found a considerable amount of variation in risk from one family to another.

Search for more genes

Among carriers, their risk of developing breast cancer by age 70 has been estimated at anywhere between 50 percent and 85 percent, Begg said.

They looked to see if perhaps the type of BRCA mutation might affect risk, but it did not appear to. Many different types of mutations were found but they usually did not significantly affect whether a woman or her relatives had breast cancer, Begg's team said.

“There's a lot of research going on at the moment in general to find additional breast cancer genes. What we're saying here is that research is likely to be successful,” Begg said.

~Andrew Stern, Reuters

The BRCA1 and BRCA2 mutations are most common among Jews of Ashken— descent. At least 2 percent of these descendants of Eastern European Jews are carriers. The incidence is lower in the general population, but not enough testing has been done to put a firm estimate on it. About 465,000 women died of breast cancer last year, making it the leading cause of cancer death among women worldwide, according to the World Health Organization.

Almost half of all cancer survivers have ill health in later years.


Oncogenic RAS mutations are found in ∼25% of human cancers and are highly prevalent in hematopoietic malignancies 22898602

Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required for tumor initiation and maintenance. 23637129

Gut Microbes. 2012 May 1;3(3). [Epub ahead of print]Microbes-induced EMT at the crossroad of inflammation and cancer.

Hofman P, Vouret-Craviari V. Source

IRCAN; France; University of Nice-Sophia Antipolis; Nice, France; Centre Hospitalier Universitaire de Nice; Hôpital Pasteur; Laboratoire de Pathologie Clinique et Expérimentale; Nice, France.


It is noteworthy that bacterial or viral infections, and the resulting chronic inflammation, have been shown to predispose individuals to certain types of cancer. Remarkably, these microbes upregulated some transcription factors involved in the regulation of the epithelial to mesenchymal transition, referred herein as EMT. EMT is a cellular process that consists in the conversion of epithelial cell phenotype to a mesenchymal phenotype. Under physiological conditions EMT is clearly important for embryogenesis, organ development, wound repair and tissue remodeling. However, EMT may also be activated under pathologic conditions, more particularly in carcinogenesis and metastatic progression. In this review, we make a parallel between microbes- and growth factors- induced transcription factors. A unifying EMT model then emerges that may help in understanding the development of microbial pathogenesis and in defining new potential future therapeutic strategy in treating diseases linked to infections.

PMID: 22572828

Somebody else found a little piece of the puzzle and is well…. puzzled.



1) , 36) , 37) , 38) , 39) , 48) , 49)
Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clin Microbiol Rev. 2010 Oct;23(4):837-57. doi: 10.1128/CMR.00012-10.
[PMID: 20930075] [PMCID: 2952975] [DOI: 10.1128/CMR.00012-10]
Steck RP, Hill SL, Weagel EG, Weber KS, Robison RA, O'Neill KL. Pharmacologic immunosuppression of mononuclear phagocyte phagocytosis by caffeine. Pharmacol Res Perspect. 2015 Oct 25;3(6):e00180. doi: 10.1002/prp2.180. eCollection 2015 Dec.
[PMID: 27022462] [PMCID: 4777255] [DOI: 10.1002/prp2.180]
Caballero B, Clay T, Davis SM, Ethelbah B, Rock BH, Lohman T, Norman J, Story M, Stone EJ, Stephenson L, Stevens J, Pathways Study Research Group. Pathways: a school-based, randomized controlled trial for the prevention of obesity in American Indian schoolchildren. Am J Clin Nutr. 2003 Nov;78(5):1030-8. doi: 10.1093/ajcn/78.5.1030.
[PMID: 14594792] [PMCID: 4863237] [DOI: 10.1093/ajcn/78.5.1030]
Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG, Erdman SE. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 2006 Aug 1;66(15):7395-400. doi: 10.1158/0008-5472.CAN-06-0558.
[PMID: 16885333] [DOI: 10.1158/0008-5472.CAN-06-0558]
Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 2011 Jan 27;6(1):e16393. doi: 10.1371/journal.pone.0016393.
[PMID: 21297998] [PMCID: 3029306] [DOI: 10.1371/journal.pone.0016393]
Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012 Oct 5;338(6103):120-3. doi: 10.1126/science.1224820. Epub 2012 Aug 16.
[PMID: 22903521] [PMCID: 3645302] [DOI: 10.1126/science.1224820]
7) , 9)
Kuper HE, Tzonou A, Kaklamani E, Hadziyannis S, Tasopoulos N, Lagiou P, Trichopoulos D, Stuver S. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control. 2000 Feb;11(2):171-5. doi: 10.1023/a:1008951901148.
[PMID: 10710202] [DOI: 10.1023/a:1008951901148]
Pinto-Santini D, Salama NR. The biology of Helicobacter pylori infection, a major risk factor for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1853-8. doi: 10.1158/1055-9965.EPI-04-0784.
[PMID: 16103425] [DOI: 10.1158/1055-9965.EPI-04-0784]
Zhan P, Suo L, Qian Q, Shen X, Qiu L, Yu L, Song Y. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. Eur J Cancer. 2011 Mar;47(5):742-7. doi: 10.1016/j.ejca.2010.11.003. Epub 2010 Dec 29.
[PMID: 21194924] [DOI: 10.1016/j.ejca.2010.11.003]
Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution?. J Urol. 2005 Jun;173(6):1969-74. doi: 10.1097/01.ju.0000158161.15277.78.
[PMID: 15879794] [DOI: 10.1097/01.ju.0000158161.15277.78]
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016 Sep;4(9):e609-16. doi: 10.1016/S2214-109X(16)30143-7. Epub 2016 Jul 25.
[PMID: 27470177] [DOI: 10.1016/S2214-109X(16)30143-7]
Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Nat Immunol. 2019 Jan 21;20(3):265-275. doi: 10.1038/s41590-018-0292-y.
[PMID: 30664738] [PMCID: 6380920] [DOI: 10.1038/s41590-018-0292-y]
Antonioli L, Haskó G, Fornai M, Colucci R, Blandizzi C. Adenosine pathway and cancer: where do we go from here?. Expert Opin Ther Targets. 2014 Sep;18(9):973-7. doi: 10.1517/14728222.2014.925883. Epub 2014 Jun 24.
[PMID: 24958495] [DOI: 10.1517/14728222.2014.925883]
15) , 30) , 32) , 33) , 34) , 82) , 83) , 84)
Syntax error [pubmed plugin]
16) , 22)
Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010 Sep 11;10:483. doi: 10.1186/1471-2407-10-483.
[PMID: 20831823] [PMCID: 2945944] [DOI: 10.1186/1471-2407-10-483]
Wang T, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorum A, Lallemant B, Zhang R, Mader S, White JH. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95. doi: 10.1210/me.2005-0106. Epub 2005 Jul 7.
[PMID: 16002434] [DOI: 10.1210/me.2005-0106]
Bikle DD. The vitamin D receptor: a tumor suppressor in skin. Discov Med. 2011 Jan;11(56):7-17.
[PMID: 21276406] [PMCID: 4113511]
Trémezaygues L, Reichrath J. From the bench to emerging new clinical concepts: Our present understanding of the importance of the vitamin D endocrine system (VDES) for skin cancer. Dermatoendocrinol. 2011 Jan;3(1):11-7. doi: 10.4161/derm.3.1.14875.
[PMID: 21519403] [PMCID: 3051847] [DOI: 10.4161/derm.3.1.14875]
20) , 21)
Pospechova K, Rozehnal V, Stejskalova L, Vrzal R, Pospisilova N, Jamborova G, May K, Siegmund W, Dvorak Z, Nachtigal P, Semecky V, Pavek P. Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. Mol Cell Endocrinol. 2009 Feb 27;299(2):178-87. doi: 10.1016/j.mce.2008.12.003. Epub 2008 Dec 24.
[PMID: 19133314] [DOI: 10.1016/j.mce.2008.12.003]
Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10;29(17):2378-85. doi: 10.1200/JCO.2010.30.9880. Epub 2011 May 2.
[PMID: 21537045] [PMCID: 3107752] [DOI: 10.1200/JCO.2010.30.9880]
Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang W, Shikany JM, Hayes RB, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008 Jun 4;100(11):796-804. doi: 10.1093/jnci/djn152. Epub 2008 May 27.
[PMID: 18505967] [PMCID: 3703748] [DOI: 10.1093/jnci/djn152]
25) , 26)
Gallicchio L, Helzlsouer KJ, Chow W, Freedman DM, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Koenig KL, Kolonel LN, Laden F, McCullough ML, Parisi D, Purdue MP, Shu X, Snyder K, Stolzenberg-Solomon RZ, Tworoger SS, Varanasi A, Virtamo J, Wilkens LR, Xiang Y, Yu K, Zeleniuch-Jacquotte A, Zheng W, Abnet CC, Albanes D, Bertrand K, Weinstein SJ. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010 Jul 1;172(1):10-20. doi: 10.1093/aje/kwq116. Epub 2010 Jun 18.
[PMID: 20562188] [PMCID: 2892539] [DOI: 10.1093/aje/kwq116]
Michaëlsson K, Baron JA, Snellman G, Gedeborg R, Byberg L, Sundström J, Berglund L, Arnlöv J, Hellman P, Blomhoff R, Wolk A, Garmo H, Holmberg L, Melhus H. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010 Oct;92(4):841-8. doi: 10.3945/ajcn.2010.29749. Epub 2010 Aug 18.
[PMID: 20720256] [DOI: 10.3945/ajcn.2010.29749]
Suzuki T, Sakabe J, Kamiya K, Funakoshi A, Tokura Y. The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells. Clin Exp Dermatol. 2018 Jun;43(4):445-448. doi: 10.1111/ced.13397. Epub 2018 Feb 1.
[PMID: 29392742] [DOI: 10.1111/ced.13397]
29) , 100)
Wakahashi K, Minagawa K, Kawano Y, Kawano H, Suzuki T, Ishii S, Sada A, Asada N, Sato M, Kato S, Shide K, Shimoda K, Matsui T, Katayama Y. Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. Blood. 2019 Apr 11;133(15):1619-1629. doi: 10.1182/blood-2018-09-876615. Epub 2019 Feb 4.
[PMID: 30718230] [DOI: 10.1182/blood-2018-09-876615]
Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab. 1997 Jan;82(1):118-22. doi: 10.1210/jcem.82.1.3642.
[PMID: 8989244] [DOI: 10.1210/jcem.82.1.3642]
Farias KPRA, Moreli ML, Floriano VG, da Costa VG. Evidence based on a meta-analysis of human cytomegalovirus infection in glioma. Arch Virol. 2019 May;164(5):1249-1257. doi: 10.1007/s00705-019-04206-z. Epub 2019 Mar 19.
[PMID: 30888562] [DOI: 10.1007/s00705-019-04206-z]
Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001 Sep;49(3):347-53. doi: 10.1136/gut.49.3.347.
[PMID: 11511555] [PMCID: 1728434] [DOI: 10.1136/gut.49.3.347]
Sutcliffe S, Platz EA. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep. 2008 May;9(3):243-9. doi: 10.1007/s11934-008-0042-z.
[PMID: 18765120] [DOI: 10.1007/s11934-008-0042-z]
Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E, Saikku P, Thoresen S, Youngman L, Paavonen J. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000 Jan 1;85(1):35-9. doi: 10.1002/(sici)1097-0215(20000101)85:1<35::aid-ijc6>3.0.co;2-a.
[PMID: 10585579] [DOI: 10.1002/(sici)1097-0215(20000101)85:1<35::aid-ijc6>3.0.co;2-a]
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001 Apr;48(4):526-35. doi: 10.1136/gut.48.4.526.
[PMID: 11247898] [PMCID: 1728259] [DOI: 10.1136/gut.48.4.526]
Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004 Feb;126(2):451-9. doi: 10.1053/j.gastro.2003.11.010.
[PMID: 14762782] [DOI: 10.1053/j.gastro.2003.11.010]
La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Franceschi S. Genital and urinary tract diseases and bladder cancer. Cancer Res. 1991 Jan 15;51(2):629-31.
[PMID: 1985779]
Mommsen S, Sell A. Prostatic hypertrophy and venereal disease as possible risk factors in the development of bladder cancer. Urol Res. 1983;11(2):49-52. doi: 10.1007/BF00256946.
[PMID: 6191422] [DOI: 10.1007/BF00256946]
Burin GJ, Gibb HJ, Hill RN. Human bladder cancer: evidence for a potential irritation-induced mechanism. Food Chem Toxicol. 1995 Sep;33(9):785-95. doi: 10.1016/0278-6915(95)00045-4.
[PMID: 7557751] [DOI: 10.1016/0278-6915(95)00045-4]
Maletzki C, Emmrich J. Inflammation and immunity in the tumor environment. Dig Dis. 2010;28(4-5):574-8. doi: 10.1159/000321062. Epub 2010 Nov 18.
[PMID: 21088404] [DOI: 10.1159/000321062]
Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood. 2015 Jan 1;125(1):82-9. doi: 10.1182/blood-2014-07-592162. Epub 2014 Oct 7.
[PMID: 25293773] [DOI: 10.1182/blood-2014-07-592162]
Lin J, Lin E, Nemunaitis J. Bacteria in the treatment of cancer. Curr Opin Mol Ther. 2004 Dec;6(6):629-39.
[PMID: 15663328]
Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I. Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23.
[PMID: 28236750] [DOI: 10.1016/j.coi.2017.01.003]
Souza-Fonseca-Guimaraes F. NK cell-based immunotherapies: awakening the innate anti-cancer response. Discov Med. 2016 Mar;21(115):197-203.
[PMID: 27115170]
Mager DL. Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med. 2006 Mar 28;4:14. doi: 10.1186/1479-5876-4-14.
[PMID: 16566840] [PMCID: 1479838] [DOI: 10.1186/1479-5876-4-14]
Zanini GM, De Moura Carvalho LJ, Brahimi K, De Souza-Passos LF, Guimarães SJ, Da Silva Machado E, Bianco-Junior C, Riccio EKP, De Sousa MA, Alecrim MDGC, Leite N, Druilhe P, Daniel-Ribeiro CT. Sera of patients with systemic lupus erythematosus react with plasmodial antigens and can inhibit the in vitro growth of Plasmodium falciparum. Autoimmunity. 2009 Sep;42(6):545-52. doi: 10.1080/08916930903039810.
[PMID: 19657771] [DOI: 10.1080/08916930903039810]
Hickson J, Diane Yamada S, Berger J, Alverdy J, O'Keefe J, Bassler B, Rinker-Schaeffer C. Societal interactions in ovarian cancer metastasis: a quorum-sensing hypothesis. Clin Exp Metastasis. 2009;26(1):67-76. doi: 10.1007/s10585-008-9177-z. Epub 2008 May 31.
[PMID: 18516689] [DOI: 10.1007/s10585-008-9177-z]
Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, Ha C, Johnson S, Kennemer MI, Mohan S, Nazarenko I, Watanabe C, Sparks AB, Shames DS, Gentleman R, de Sauvage FJ, Stern H, Pandita A, Ballinger DG, Drmanac R, Modrusan Z, Seshagiri S, Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010 May 27;465(7297):473-7. doi: 10.1038/nature09004.
[PMID: 20505728] [DOI: 10.1038/nature09004]
Ponder BA. Cancer genetics. Nature. 2001 May 17;411(6835):336-41. doi: 10.1038/35077207.
[PMID: 11357140] [DOI: 10.1038/35077207]
60) , 66)
Cochran GM, Ewald PW, Cochran KD. Infectious causation of disease: an evolutionary perspective. Perspect Biol Med. 2000 Spring;43(3):406-48. doi: 10.1353/pbm.2000.0016.
[PMID: 10893730] [DOI: 10.1353/pbm.2000.0016]
Poulsen P, Esteller M, Vaag A, Fraga MF. The epigenetic basis of twin discordance in age-related diseases. Pediatr Res. 2007 May;61(5 Pt 2):38R-42R. doi: 10.1203/pdr.0b013e31803c7b98.
[PMID: 17413848] [DOI: 10.1203/pdr.0b013e31803c7b98]
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000 Jul 13;343(2):78-85. doi: 10.1056/NEJM200007133430201.
[PMID: 10891514] [DOI: 10.1056/NEJM200007133430201]
Hemminki K, Lorenzo Bermejo J, Försti A. The balance between heritable and environmental aetiology of human disease. Nat Rev Genet. 2006 Dec;7(12):958-65. doi: 10.1038/nrg2009.
[PMID: 17139327] [DOI: 10.1038/nrg2009]
Uemura N, Okamoto S, Yamamoto S. H. pylori infection and the development of gastric cancer. Keio J Med. 2002 Dec;51 Suppl 2:63-8. doi: 10.2302/kjm.51.supplement2_63.
[PMID: 12528941] [DOI: 10.2302/kjm.51.supplement2_63]
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006 Jun 15;118(12):3030-44. doi: 10.1002/ijc.21731.
[PMID: 16404738] [DOI: 10.1002/ijc.21731]
Mackay HL, Moore D, Hall C, Birkbak NJ, Jamal-Hanjani M, Karim SA, Phatak VM, Piñon L, Morton JP, Swanton C, Le Quesne J, Muller PAJ. Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nat Commun. 2018 Aug 3;9(1):3070. doi: 10.1038/s41467-018-05368-1.
[PMID: 30076358] [PMCID: 6076230] [DOI: 10.1038/s41467-018-05368-1]
Sapkota AR, Berger S, Vogel TM. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ Health Perspect. 2010 Mar;118(3):351-6. doi: 10.1289/ehp.0901201. Epub 2009 Oct 22.
[PMID: 20064769] [PMCID: 2854762] [DOI: 10.1289/ehp.0901201]
Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol. 1998 Mar 15;83(1-2):148-56. doi: 10.1016/s0165-5728(97)00231-2.
[PMID: 9610683] [DOI: 10.1016/s0165-5728(97)00231-2]
Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002 May;2(5):372-7. doi: 10.1038/nri803.
[PMID: 12033743] [DOI: 10.1038/nri803]
71) , 72)
Forchuk C, Norman R, Malla A, Martin M, McLean T, Cheng S, Diaz K, McIntosh E, Rickwood A, Vos S, Gibney C. Schizophrenia and the motivation for smoking. Perspect Psychiatr Care. 2002 Apr-Jun;38(2):41-9. doi: 10.1111/j.1744-6163.2002.tb00656.x.
[PMID: 12132630] [DOI: 10.1111/j.1744-6163.2002.tb00656.x]
73) , 95)
Yue Z, Yun-Shan Z, Feng-Xia X. miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. J Renin Angiotensin Aldosterone Syst. 2016 Jul-Sep;17(3):1470320316663327. doi: 10.1177/1470320316663327.
[PMID: 28304186] [PMCID: 5843885] [DOI: 10.1177/1470320316663327]
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010 Jul;11(7):627-36. doi: 10.1016/S1470-2045(10)70106-6. Epub 2010 Jun 11.
[PMID: 20542468] [PMCID: 4070221] [DOI: 10.1016/S1470-2045(10)70106-6]
Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011 Apr 26;123(16):1729-36. doi: 10.1161/CIRCULATIONAHA.110.007336. Epub 2011 Apr 11.
[PMID: 21482967] [DOI: 10.1161/CIRCULATIONAHA.110.007336]
Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011 Mar 28;17(12):1531-7. doi: 10.3748/wjg.v17.i12.1531.
[PMID: 21472116] [PMCID: 3070121] [DOI: 10.3748/wjg.v17.i12.1531]
Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer. 2008 Apr;50(4):896-8. doi: 10.1002/pbc.21202.
[PMID: 17458875] [DOI: 10.1002/pbc.21202]
Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7. doi: 10.1038/sj.onc.1210911.
[PMID: 18176597] [DOI: 10.1038/sj.onc.1210911]
Dalpke A, Frank J, Peter M, Heeg K. Activation of toll-like receptor 9 by DNA from different bacterial species. Infect Immun. 2006 Feb;74(2):940-6. doi: 10.1128/IAI.74.2.940-946.2006.
[PMID: 16428738] [PMCID: 1360326] [DOI: 10.1128/IAI.74.2.940-946.2006]
Osborne GEN, Mallon E, Mayou SC. Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol. 2003 May;48(5 Suppl):S99-102. doi: 10.1067/mjd.2003.158.
[PMID: 12734491] [DOI: 10.1067/mjd.2003.158]
Greally JF, Manning D, McNicholl B. Sarcoidosis following B.C.G. vaccination in a lymphopaenic boy. Sarcoidosis. 1989 Sep;6(2):156-7.
[PMID: 2602688]
Nam J, Park S, Lee H, Lee S, Jang H, Rhee YH. Correlation Between Acetogenin Content and Antiproliferative Activity of Pawpaw (Asimina triloba [L.] Dunal) Fruit Pulp Grown in Korea. J Food Sci. 2018 May;83(5):1430-1435. doi: 10.1111/1750-3841.14144. Epub 2018 Apr 16.
[PMID: 29660776] [DOI: 10.1111/1750-3841.14144]
Nam J, Park S, Oh H, Jang H, Rhee YH. Phenolic Profiles, Antioxidant and Antimicrobial Activities of Pawpaw Pulp (Asimina triloba [L.] Dunal) at Different Ripening Stages. J Food Sci. 2019 Jan;84(1):174-182. doi: 10.1111/1750-3841.14414. Epub 2018 Dec 17.
[PMID: 30557901] [DOI: 10.1111/1750-3841.14414]
Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, MacKay A, A'Hern R, Gauthier A, Pawar V, Colombo P, Daley F, Natrajan R, Ward E, MacGrogan G, Arbion F, Michenet P, Weigelt B, Vincent-Salomon A, Reis-Filho JS. Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.
[PMID: 22025283] [PMCID: 4962905] [DOI: 10.1002/path.3032]
Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, Nelson WG, De Marzo AM, Cole SR, Isaacs WB, Platz EA. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol. 2006 May;175(5):1937-42. doi: 10.1016/S0022-5347(05)00892-X.
[PMID: 16600802] [DOI: 10.1016/S0022-5347(05)00892-X]
Delfarah A, Parrish S, Junge JA, Yang J, Seo F, Li S, Mac J, Wang P, Fraser SE, Graham NA. Inhibition of nucleotide synthesis promotes replicative senescence of human mammary epithelial cells. J Biol Chem. 2019 Jul 5;294(27):10564-10578. doi: 10.1074/jbc.RA118.005806. Epub 2019 May 28.
[PMID: 31138644] [PMCID: 6615688] [DOI: 10.1074/jbc.RA118.005806]
Wanderley CW, Colón DF, Luiz JPM, Oliveira FF, Viacava PR, Leite CA, Pereira JA, Silva CM, Silva CR, Silva RL, Speck-Hernandez CA, Mota JM, Alves-Filho JC, Lima-Junior RC, Cunha TM, Cunha FQ. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. Cancer Res. 2018 Oct 15;78(20):5891-5900. doi: 10.1158/0008-5472.CAN-17-3480. Epub 2018 Aug 13.
[PMID: 30104241] [DOI: 10.1158/0008-5472.CAN-17-3480]
Ambroziak A, Cichosz G. [Immune stimulative potency of milk proteins]. Pol Merkur Lekarski. 2014 Feb;36(212):133-6.
[PMID: 24720113]
Wang C, Wang B, Hou S, Xue L, Kang Z, Du J, Li Y, Liu X, Wang Q, Zhang C. Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. Eur J Med Chem. 2019 Feb 1;163:787-803. doi: 10.1016/j.ejmech.2018.12.024. Epub 2018 Dec 14.
[PMID: 30579121] [DOI: 10.1016/j.ejmech.2018.12.024]
Bakhtiari E, Hosseini A, Boroushaki MT, Mousavi SH. Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line. J Chemother. 2016 Aug;28(4):314-20. doi: 10.1179/1973947815Y.0000000055.
[PMID: 26138656] [DOI: 10.1179/1973947815Y.0000000055]
Busby J, McMenamin Ú, Spence A, Johnston BT, Hughes C, Cardwell CR. Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. Aliment Pharmacol Ther. 2018 Jan;47(2):279-288. doi: 10.1111/apt.14388. Epub 2017 Nov 3.
[PMID: 29105106] [DOI: 10.1111/apt.14388]
Sivaprakasam S, Prasad PD, Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol Ther. 2016 Aug;164:144-51. doi: 10.1016/j.pharmthera.2016.04.007. Epub 2016 Apr 23.
[PMID: 27113407] [PMCID: 4942363] [DOI: 10.1016/j.pharmthera.2016.04.007]
Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: Evidence of association and causality. Semin Immunol. 2017 Aug;32:25-34. doi: 10.1016/j.smim.2017.08.001. Epub 2017 Aug 16.
[PMID: 28822617] [PMCID: 5660659] [DOI: 10.1016/j.smim.2017.08.001]
Yamane T, Sakamoto T, Nakagaki T, Nakano Y. Lactic Acid Bacteria from Kefir Increase Cytotoxicity of Natural Killer Cells to Tumor Cells. Foods. 2018 Mar 27;7(4):48. doi: 10.3390/foods7040048.
[PMID: 29584690] [PMCID: 5920413] [DOI: 10.3390/foods7040048]
Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BH, Ivanisevic J, Cho K, Wick EC, Hechenbleikner EM, Uritboonthai W, Goetz L, Casero RAJ, Pardoll DM, White JR, Patti GJ, Sears CL, Siuzdak G. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015 Jun 2;21(6):891-7. doi: 10.1016/j.cmet.2015.04.011. Epub 2015 May 7.
[PMID: 25959674] [PMCID: 4456201] [DOI: 10.1016/j.cmet.2015.04.011]
Fiolet T, Srour B, Sellem L, Kesse-Guyot E, Allès B, Méjean C, Deschasaux M, Fassier P, Latino-Martel P, Beslay M, Hercberg S, Lavalette C, Monteiro CA, Julia C, Touvier M. Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort. BMJ. 2018 Feb 14;360:k322. doi: 10.1136/bmj.k322.
[PMID: 29444771] [PMCID: 5811844] [DOI: 10.1136/bmj.k322]
Zhang H. Will cancer cells be defeated by sodium bicarbonate?. Sci China Life Sci. 2017 Mar;60(3):326-328. doi: 10.1007/s11427-016-0373-3. Epub 2017 Jan 4.
[PMID: 28083722] [PMCID: 5954837] [DOI: 10.1007/s11427-016-0373-3]
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005 Oct;5(10):749-59. doi: 10.1038/nri1703.
[PMID: 16175180] [DOI: 10.1038/nri1703]
home/diseases/cancer.txt · Last modified: 09.14.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.